Skip to content

Routine Staple Line Reinforcement for Minimally Invasive Distal Pancreatectomy

Efficacy of Routine Staple Line Reinforcement Versus no Reinforcement on Pancreatic Fistula After Minimally Invasive Distal Pancreatectomy: A Single Center, Parallel, Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04663789
Acronym
Double-Lock
Enrollment
124
Registered
2020-12-11
Start date
2020-12-01
Completion date
2023-05-30
Last updated
2021-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Neoplasm, Stump, Surgery--Complications

Keywords

Staple line, Reinforcement, Pancreatic fistula

Brief summary

Postoperative fistula is the major complications of distal pancreatectomies which prohibit patients' recovery. Previous studies have reported controversial results regarding the efficacy of pancreatic stump reinforcement methods. Prior research has commonly included minimally invasive and open cases together. Moreover, stapler and suture were combined in most studies making interpretation difficult. Data has shown that staple line plus reinforcement might potentially decrease the CR-POPF rate of patients who underwent distal pancreatectomies, but well-designed high-quality evidence is lacking. Thus, the investigators design the present study to the question that whether routine staple line plus reinforcement would bring benefit for participants.

Detailed description

Distal pancreatectomy (DP)is the standard surgical method for benign or malignant pancreatic tumors locating at body and tail \[1\]. Clinically relevant postoperative pancreatic fistula (CR-POPF) is the major complication after pancreatectomy. In literature, reported CR-POPF rate after distal pancreatectomy varied between 5% and 64% from different centers. It's still a challenge to prevent CR-POPF via effective pancreatic remnant closure and no consensus on the optimal surgical technique has been established. Reported surgical strategies to prevent CR-POPF included stapler transection, staple line reinforcement, stump coverage with autologous tissue or fibrin glue, mesh reinforcement, and prophylactic administration of octreotide. However, none had convincing outcome \[2-4\]. Data has shown that staple line plus suture reinforcement might potentially decrease the CR-POPF rate of patients who underwent distal pancreatectomies, but well-designed high-quality evidence is lacking. Meanwhile, prior researches have commonly included minimally invasive and open cases together. Moreover, stapler and suture were combined in most studies making interpretation difficult \[5-8\]. Thus, the investigators design a single-centered, parallel, randomized controlled trial to compare the efficacy of routine staple line plus reinforcement versus staple only on the CR-POPF rate of participants who underwent minimally invasive distal pancreatectomies.

Interventions

PROCEDUREreinforcement of the staple line

The operator will perform reinforcement of the staple line with a continuous lock stitch.

PROCEDUREstaple only

The operator transect the pancreas with stapler only, without staple line reinforcement.

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

It will be single blinded. Operator, first assistant and data collector could not be blinded. Whereas patients, nurses, data analyzer, and those who have the access to the primary predictor will be blinded.

Intervention model description

The study is a single-center, randomized controlled clinical trial. Grouping: the study group is set as staple line plus reinforcement group, in which a lock stitch will be placed after transecting the pancreas with stapler. While the control group is set as staple line with no reinforcement group, in which no additional reinforcement is used after transecting the pancreas with stapler.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Those who will receive distal pancreatectomy via minimally invasive approaches, no matter benign or malignant; * Aged from 18 - 80 years; * Preoperative diagnosis of serous or mucinous cystic adenoma; * Preoperative diagnosis of solid pseudopapillary tumor (SPT); * Preoperative diagnosis of neuroendocrine tumor; * Preoperative diagnosis of intraductal papillary mucinous neoplasm (IPMN); * Preoperative diagnosis of or pseudocyst; * Preoperative diagnosis of distal pancreatic malignancies; * Patients willing to provide informed consent.

Exclusion criteria

* History of upper abdominal surgical history such as splenectomy, gastrectomy, liver resection, duodenal or pancreatic resection (not including laparoscopic cystectomy); * Pancreatic trauma; * With pneumoperitoneum contraindications; * With severe heart or pulmonary diseases which is not fit for surgeries.

Design outcomes

Primary

MeasureTime frameDescription
Clinically relevant postoperative pancreatic fistula (CR-POPF)Postoperative postoperative day 30.CR-POPF is defined according to the revised 2016 version of ISGPS (International Study Group on Pancreatic Surgery) classification and grading of POPF. A CR-POPF is defined as a drain output of any measurable volume of fluid with amylase level greater than 3 times the upper Institutional normal serum amylase level, associated with a clinically relevant development/condition related directly to the POPF.

Secondary

MeasureTime frameDescription
Length of postoperative hospital stayPostoperative postoperative day 30.Days of hospital stay after surgery
Operative timePostoperative postoperative day 30.Skin-to-skin time
Estimated blood lossPostoperative postoperative day 30.Total blood loss during surgery

Countries

China

Contacts

Primary ContactFeng Tian, Doctor
andytianfeng@126.com+86-01069152600
Backup ContactJun Lu, Doctor
pumchtf@sina.com+86-01069152601

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026